NEAR-INFRARED SUPER-CONTINUUM LASERS FOR EARLY DETECTION OF BREAST AND OTHER CANCERS

• US 20140236021A1
• Filed: 12/17/2013
• Published: 08/21/2014
• Est. Priority Date: 12/31/2012
• Status: Active Grant

• Current Assignee: Omni Medsci, Inc.
• Original Assignee: Omni Medsci, Inc.
• Inventors: Islam, Mohammed N.
• Granted Patent: US 9,993,159 B2
• Time in Patent Office: Days
• US Class Current: 600/475
• CPC Class Codes: A61B 2562/0238 Optical sensor arrangements for performing transmission measurements on body tissue
• CPC Class Codes: A61B 5/0075 by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy A61B5/0071 takes precedence
• CPC Class Codes: A61B 5/0091 for mammography

Abstract

A system and method for using near-infrared or short-wave infrared (SWIR) light sources for early detection and monitoring of breast cancer, as well as other kinds of cancers may detect decreases in lipid content and increases in collagen content, possibly with a shift in the collagen peak wavelengths and changes in spectral features associated with hemoglobin and water content as well. Wavelength ranges between 1000-1400 nm and 1600-1800 nm may permit relatively high penetration depths because they fall within local minima of water absorption, scattering loss decreases with increasing wavelength, and they have characteristic signatures corresponding to overtone and combination bands from chemical bonds of interest, such as hydrocarbons. Broadband light sources and detectors permit spectroscopy in transmission, reflection, and/or diffuse optical tomography. High signal-to-noise ratio may be achieved using a fiber-based super-continuum light source. Risk of pain or skin damage may be mitigated using surface cooling and focused infrared light.

Claims

1. A diagnostic system comprising:

a light source configured to generate an output optical beam, comprising;

one or more semiconductor sources configured to generate an input beam;

one or more optical amplifiers configured to receive at least a portion of the input beam and to deliver an intermediate beam to an output end of the one or more optical amplifiers;

one or more optical fibers configured to receive at least a portion of the intermediate beam and to deliver at least the portion of the intermediate beam to a distal end of the one or more optical fibers to form a first optical beam;

a nonlinear element configured to receive at least a portion of the first optical beam and to broaden a spectrum associated with the at least a portion of the first optical beam to at least 10 nanometers through a nonlinear effect in the nonlinear element to form the output optical beam with an output beam broadened spectrum; and

wherein at least a portion of the output beam broadened spectrum comprises a short-wave infrared wavelength between approximately 1000 nanometers and approximately 1400 nanometers or between approximately 1600 nanometers and approximately 1800 nanometers, and wherein at least a portion of the one of more fibers is a fused silica fiber with a core diameter less than approximately 400 microns;

an interface device configured to receive a received portion of the output optical beam and to deliver a delivered portion of the output optical beam to a tissue sample, wherein the delivered portion of the output optical beam is configured to generate a spectroscopy output beam from the tissue sample, and wherein at least a part of the delivered portion of the output optical beam penetrates into the tissue sample a depth of two (2) millimeters or more; and

a receiver configured to receive at least a portion of the spectroscopy output beam having a bandwidth of at least 10 nanometers and to process the portion of the spectroscopy output beam to generate an output signal representing at least in part a composition of collagen and lipids in the tissue sample.

2. The system of claim 1, wherein the spectroscopy output beam is based at least in part on diffuse light spectroscopy, and the tissue sample is breast, skin, prostate, brain, pancreatic or colorectal tissue.

3. The system of claim 1, wherein the semiconductor sources are selected from the group consisting of semiconductor lasers, super-luminescent diodes, and light emitting diodes.

4. The system of claim 1, wherein the interface device further comprises a surface cooling apparatus or a light focusing apparatus.

5. The system of claim 1, wherein the receiver further comprises a Fourier transform infrared (FTIR) spectrometer or a dispersive spectrometer.

6. A measurement system comprising:

a light source configured to generate an output optical beam, comprising;

a plurality of semiconductor sources configured to generate an input optical beam;

a multiplexer configured to receive at least a portion of the input optical beam and to form an intermediate optical beam; and

one or more fibers configured to receive at least a portion of the intermediate optical beam and to form the output optical beam, wherein the output optical beam comprises one or more optical wavelengths;

an interface device configured to receive a received portion of the output optical beam and to deliver a delivered portion of the output optical beam to a tissue sample, wherein the delivered portion of the output optical beam is configured to generate a spectroscopy output beam from the sample based on diffuse light spectroscopy, and wherein at least a part of the delivered portion of the output optical beam penetrates into the tissue sample a depth of two (2) millimeters or more; and

a receiver configured to receive at least a portion of the spectroscopy output beam and to process the portion of the spectroscopy output beam to generate an output signal, wherein the output signal is based on a chemical composition of the tissue sample.

7. The system of claim 6, wherein the light source comprises a super-continuum laser.

8. The system of claim 6, wherein the semiconductor sources are selected from the group consisting of semiconductor lasers, super-luminescent diodes, and light emitting diodes.

9. The system of claim 6, wherein the interface device is configured for a non-invasive measurement.

10. The system of claim 6, wherein at least a portion of the one of more optical wavelengths comprises a short-wave infrared wavelength between approximately 1000 nanometers and approximately 1400 nanometers or between approximately 1600 nanometers and approximately 1800 nanometers.

11. The system of claim 6, wherein the chemical composition of the tissue sample comprises lipid, collagen, water, blood or protein.

12. The system of claim 6, wherein the output signal is configured to diagnose cancer in at least a part of the tissue sample based on a change in composition of collagen and lipids.

13. The system of claim 6, wherein the interface device further comprises a surface cooling apparatus or a light focusing apparatus.

14. The system of claim 6, wherein the spectroscopy output beam has a bandwidth of at least 10 nanometers.

15. The system of claim 6, wherein the receiver further comprises a Fourier transform infrared (FTIR) spectrometer or a dispersive spectrometer.

16. The system of claim 6, wherein the tissue sample is breast, skin, prostate, brain, pancreatic or colorectal tissue.

17. A method of measuring, comprising:

generating an output optical beam, comprising;

generating an input optical beam from a plurality of semiconductor sources;

multiplexing at least a portion of the input optical beam and forming an intermediate optical beam; and

guiding at least a portion of the intermediate optical beam and forming the output optical beam, wherein the output optical beam comprises one or more optical wavelengths, wherein at least a portion of the optical wavelengths is between approximately 1000 nanometers and 1400 nanometers or between approximately 1600 nanometers and 1800 nanometers;

receiving a received portion of the output optical beam and delivering a delivered portion of the output optical beam to a tissue sample;

generating a spectroscopy output beam having a bandwidth of at least 10 nanometers from the tissue sample;

receiving at least a portion of the spectroscopy output beam; and

processing the portion of the spectroscopy output beam and generating an output signal based on a wavelength dependence of the spectroscopy output beam over the bandwidth of at least 10 nanometers, and wherein the output signal is based on a chemical composition of the tissue sample.

18. The method of claim 17, wherein at least a part of the delivered portion of the output optical beam penetrates the tissue sample by two (2) millimeters or more, and wherein the spectroscopy output beam is based on diffuse light spectroscopy.

19. The method of claim 17, further comprising cooling at least a part of the tissue sample or focusing the delivered portion of the output optical beam onto the tissue sample.

20. The method of claim 17, wherein the output signal is configured to diagnose cancer in at least a part of the tissue sample.